A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects.

Trial Profile

A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Atopaxar (Primary) ; Metformin
  • Indications Diabetes mellitus; Thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 31 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top